ENLV
Enlivex Therapeutics Ltd
NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY
$0.82
-0.46% today
Updated 2026-05-01
Market cap
$197.61M
P/E ratio
0.03
P/S ratio
—
EPS (TTM)
$25.48
Dividend yield
—
52W range
$1 – $2
Volume
0.6M
Enlivex Therapeutics Ltd (ENLV) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.14M | $13.53M | $14.53M | $25.30M | $17.18M | $18.73M | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $2.28M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -25.4% | +7.4% | +74.1% | -32.1% | +9.0% | -100.0% | — | — | — | — | — | — | — | — | -100.0% | — | — | — | — |
| Cost of revenue | $3.94M | $5.87M | $3.26M | $7.15M | $6.43M | $8.81M | — | — | $5000.00 | $17000.00 | $25000.00 | $12000.00 | $121000.00 | $297000.00 | $286000.00 | $546000.00 | $777000.00 | $835000.00 | $545000.00 | $332000.00 |
| Gross profit | $14.20M | $7.66M | $11.28M | $18.14M | $10.75M | $9.92M | — | — | $-5000.00 | $-17000.00 | $-25000.00 | $-12000.00 | $-121000.00 | $-297000.00 | $-286000.00 | $-546000.00 | $-777000.00 | $-835000.00 | $-545000.00 | $-332000.00 |
| Gross margin | 78.3% | 56.6% | 77.6% | 71.7% | 62.6% | 52.9% | — | — | — | — | — | — | — | — | -12.6% | — | — | — | — | — |
| R&D | $5.55M | $4.21M | $3.43M | $4.48M | $3.92M | $3.27M | $140000.00 | $732000.00 | $4.44M | $7.69M | $8.88M | $2.52M | $4.25M | $5.72M | $6.09M | $12.88M | $18.69M | $19.23M | $10.13M | $8.92M |
| SG&A | $31.36M | $24.48M | $14.38M | $19.65M | $18.28M | $17.21M | — | $416000.00 | $2.64M | $6.95M | $6.99M | $2.96M | $937000.00 | $2.75M | $3.60M | $6.24M | $6.70M | $6.14M | $4.91M | $5.68M |
| Operating income | — | — | — | — | — | — | $-226000.00 | $-1.15M | $-7.08M | $-15.48M | $-15.87M | $-5.96M | $-5.30M | $-8.62M | $-9.79M | $-19.29M | $-25.80M | $-29.39M | $-15.54M | $-15.00M |
| Operating margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | -429.7% | — | — | — | — | — |
| EBITDA | — | — | — | — | — | — | $-226000.00 | $-1.14M | $-7.08M | $-15.31M | $-15.78M | $-5.91M | $-5.18M | $-9.08M | $-9.50M | $-18.74M | $-25.02M | $-28.22M | $-14.47M | $-14.67M |
| EBITDA margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | -417.2% | — | — | — | — | — |
| EBIT | — | — | — | — | — | — | $-226000.00 | $-1.15M | $-7.08M | $-15.33M | $-15.81M | $-5.92M | $-5.30M | $-9.38M | $-9.79M | $-19.29M | $-25.80M | $-29.05M | $-15.01M | $-15.00M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7000.00 | $6000.00 | $328000.00 | $5.26M | $14000.00 | $13000.00 | $13000.00 |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | — | — | — | — | — | $-229000.00 | $-1.15M | $-7.02M | $-15.37M | $-16.02M | $-5.95M | $-4.90M | $-9.38M | $-11.82M | $-14.47M | $-31.06M | $-29.07M | $-15.01M | $1.24B |
| Net income growth (YoY) | — | — | — | — | — | — | — | -400.0% | -513.3% | -118.8% | -4.3% | +62.9% | +17.6% | -91.5% | -26.0% | -22.4% | -114.7% | +6.4% | +48.3% | +8329.2% |
| Profit margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | -519.3% | — | — | — | — | — |